Literature DB >> 8731424

Increased density of dopamine D5 receptor in peripheral blood lymphocytes of migraineurs: a marker for migraine?

P Barbanti1, E Bronzetti, A Ricci, R Cerbo, G Fabbrini, M G Buzzi, F Amenta, G L Lenzi.   

Abstract

The expression of dopamine D5 receptor was investigated in peripheral blood lymphocytes of 11 migraine patients and of ten healthy control subjects using a radioligand binding technique with [3H]SCH 23390 as a ligand. [3H]SCH 23390 is a benzazepine derivative with potent antagonist properties at the dopamine D1-like receptors. [3H]SCH 23390 was specifically bound to peripheral blood lymphocytes of migraineurs and control subjects in a manner consistent with the labelling of a dopamine D5 receptor. In migraineurs a statistically significant higher density of lymphocyte dopamine D5 receptor compared with controls was noticeable, whereas the affinity of the radioligand was unchanged. The increased density of dopamine D5 receptor in peripheral blood lymphocytes may reflect the dopaminergic hypersensitivity displayed by migraineurs and may represent a relatively simple and reliable peripheral marker of altered dopaminergic function.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8731424     DOI: 10.1016/0304-3940(96)12491-5

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  10 in total

1.  D1 and D2 dopamine receptor-mediated inhibition of activated normal T cell proliferation is lost in jurkat T leukemic cells.

Authors:  Biswarup Basu; Chandrani Sarkar; Debanjan Chakroborty; Subhalakshmi Ganguly; Saurav Shome; Partha Sarathi Dasgupta; Sujit Basu
Journal:  J Biol Chem       Date:  2010-06-30       Impact factor: 5.157

Review 2.  Close encounters of the monoamine kind: immune cells betray their nervous disposition.

Authors:  Elizabeth J Meredith; Anita Chamba; Michelle J Holder; Nicholas M Barnes; John Gordon
Journal:  Immunology       Date:  2005-07       Impact factor: 7.397

3.  Immunomodulatory Effect of Toll-Like Receptor-3 Ligand Poly I:C on Cortical Spreading Depression.

Authors:  Amir Ghaemi; Azadeh Sajadian; Babak Khodaie; Ahmad Ali Lotfinia; Mahmoud Lotfinia; Afsaneh Aghabarari; Maryam Khaleghi Ghadiri; Sven Meuth; Ali Gorji
Journal:  Mol Neurobiol       Date:  2014-11-23       Impact factor: 5.590

Review 4.  Current and prospective pharmacological targets in relation to antimigraine action.

Authors:  Suneet Mehrotra; Saurabh Gupta; Kayi Y Chan; Carlos M Villalón; David Centurión; Pramod R Saxena; Antoinette MaassenVanDenBrink
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-15       Impact factor: 3.000

Review 5.  Dopaminergic symptoms in migraine.

Authors:  Piero Barbanti; L Fofi; C Aurilia; G Egeo
Journal:  Neurol Sci       Date:  2013-05       Impact factor: 3.307

6.  The dopaminergic system in peripheral blood lymphocytes: from physiology to pharmacology and potential applications to neuropsychiatric disorders.

Authors:  Francesca R Buttarelli; Alessandra Fanciulli; Clelia Pellicano; Francesco E Pontieri
Journal:  Curr Neuropharmacol       Date:  2011-06       Impact factor: 7.363

7.  Headaches from cellular telephones: are they real and what are the implications?

Authors:  A H Frey
Journal:  Environ Health Perspect       Date:  1998-03       Impact factor: 9.031

8.  Studies on the pathophysiology and genetic basis of migraine.

Authors:  Claudia F Gasparini; Heidi G Sutherland; Lyn R Griffiths
Journal:  Curr Genomics       Date:  2013-08       Impact factor: 2.236

9.  Mobile Phone Use and The Risk of Headache: A Systematic Review and Meta-analysis of Cross-sectional Studies.

Authors:  Jing Wang; Hui Su; Wei Xie; Shengyuan Yu
Journal:  Sci Rep       Date:  2017-10-03       Impact factor: 4.379

Review 10.  A link between gastrointestinal disorders and migraine: Insights into the gut-brain connection.

Authors:  Sheena K Aurora; Stephen B Shrewsbury; Sutapa Ray; Nada Hindiyeh; Linda Nguyen
Journal:  Headache       Date:  2021-04-01       Impact factor: 5.887

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.